Pfizer announced Monday that sigvotatug vedotin, the first new ADC to read out pivotal data following its $43 billion acquisition of Seagen, has stumbled in a phase 3 study in non-small cell lung cancer.
- Home |
- Pfizer’s first new ADC from Seagen acquisition fails phase 3 NSCLC trial
Pfizer’s first new ADC from Seagen acquisition fails phase 3 NSCLC trial
- June 22, 2026
Recent Posts
- Oil jumps 5% as Hormuz tanker attacks escalate, US Gulf hurricane shuts in production
- Crescent Energy to acquire Eagle Ford assets from Devon for $4.2 billion
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
